Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines

Business Wire12-11

MARLBOROUGH, Mass., December 10, 2024--(BUSINESS WIRE)--Hologic, Inc., (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490026491?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fi7BsJmr5FM9MGKrVU50lg--~B/aD0yODQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/26ad6843b8fc99e7e6843f6ec729e434","is_english":true,"pubTime":"2024-12-11 05:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490026491","market":"us","top_or_hot":-1,"title":"Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines","media":"Business Wire","content":"<div>\n<p>MARLBOROUGH, Mass., December 10, 2024--(BUSINESS WIRE)--Hologic, Inc., (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hologic-statement-uspstf-draft-cervical-210100400.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 05:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hologic-statement-uspstf-draft-cervical-210100400.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MARLBOROUGH, Mass., December 10, 2024--(BUSINESS WIRE)--Hologic, Inc., (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hologic-statement-uspstf-draft-cervical-210100400.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.yahoo.com/news/hologic-statement-uspstf-draft-cervical-210100400.html","article_id":"2490026491","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fi7BsJmr5FM9MGKrVU50lg--~B/aD0yODQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/26ad6843b8fc99e7e6843f6ec729e434"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490026491","pubTimestamp":1733864460,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"MARLBOROUGH, Mass., December 10, 2024----Hologic, Inc.,  a global leader in women’s health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening:. \"Today’s recommendations are an important acknowledgement of the role of Pap testing combined with HPV testing, which is the gold standard of care and the most effective method of identifying cervical cancer,\" said Jennifer Schneiders, PhD, President, Diagnostic Solutions at Hologic. \"Eliminating cervical cancer is within our reach and history has shown us that safeguarding the most comprehensive screening available is critical to that effort.\". Hologic is committed to working with USPSTF and others within the cervical cancer community in support of final screening guidelines that preserve all screening options, improving our ability to co","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","BK4588":"碎股","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4121":"生命科学工具和服务","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","HOLX":"豪洛捷","BK4082":"医疗保健设备","SEER":"Seer, Inc."},"translate_title":"Hologic关于USPSTF宫颈癌筛查指南草案的声明","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOLX":1,"SEER":1},"content_text":"MARLBOROUGH, Mass., December 10, 2024--(BUSINESS WIRE)--Hologic, Inc., (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening:\n\"Today’s recommendations are an important acknowledgement of the role of Pap testing combined with HPV testing, which is the gold standard of care and the most effective method of identifying cervical cancer,\" said Jennifer Schneiders, PhD, President, Diagnostic Solutions at Hologic. \"Eliminating cervical cancer is within our reach and history has shown us that safeguarding the most comprehensive screening available is critical to that effort.\"\nOnce the leading cause of cancer death in women, cervical cancer mortality rates have plummeted by 70% mainly due to cervical cancer screening.1 Despite this progress, cervical cancer incidence is no longer declining and cases continue to disproportionately impact Black and Hispanic women, making a focus on routine screening and vaccination imperative.2-4\nMultiple studies and other research representative of real-world screening practices in the US demonstrate that screening women ages 30-65 with the Pap test combined with HPV test identifies more cervical pre-cancer and cancer than either test used alone.5-8 The draft recommendations reinforce the value of all three cervical cancer screening strategies for women including Pap testing for women ages 21-29 years old.9 The draft recommendations also continue to allow for shared decision-making between healthcare providers and patients and help ensure that women can continue to access the preventive care they need and deserve.\nHologic is committed to working with USPSTF and others within the cervical cancer community in support of final screening guidelines that preserve all screening options, improving our ability to combat this preventable cancer and save more women’s lives.\nAbout Hologic\nHologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnosis and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X (Twitter), Instagram and YouTube.\nSOURCE: Hologic, Inc.\nReferences\n\nAmerican Cancer Society. Cancer Statistics Center. https://cancerstatisticscenter.cancer.org/?_ga=2.150839477.2044751383.1547156654-294386523.1544563210#!/. Accessed December 4, 2024.\nSurveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER Research Data, 8 Registries, Nov 2023 Sub (1975-2021). Accessed December 4, 2024. https://seer.cancer.gov/statfacts/html/cervix.html\nBeavis AL, Gravitt PE. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123(6):1044-1050.\nOffice of Minority Health, US Department of Health and Human Services. Cancer and Hispanic Americans. https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=61. Accessed December 4, 2024.\nAustin RM, et al. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV co-testing. Am J Clin Pathol.2018;150(5):385-392. doi: 10.1093/ajcp/aqy114\nBlatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/ cncy.21544\nKaufman H, et al. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074\nZhou H, et al. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions. Cancer Cytopathol. 2016 May;124(5):317-23. doi: 10.1002/cncy.21687.\nU.S. Preventive Services Task Force. Draft Recommendation Statement. Cervical Cancer Screening. December 10, 2024. https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/cervical-cancer-screening-adults-adolescents\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241210733407/en/\nContacts\nInvestor Contact Ryan SimonVice President, Investor Relations+1 858.410.8514ryan.simon@hologic.com\nMedia Contact Bridget PerrySenior Director, Corporate Communications+1 508.263.8654bridget.perry@hologic.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490026491"}